Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib

Abstract Background Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patien...

Full description

Saved in:
Bibliographic Details
Main Authors: Mengqiu Tang, Chao Song, Yaowen Zhang, Xiaoyu Xu, Chen Wang, Zhanchun Zhang, Tian Chen
Format: article
Language:EN
Published: BMC 2021
Subjects:
Online Access:https://doaj.org/article/6fe58de71bfe4ffa81cf84773b662752
Tags: Add Tag
No Tags, Be the first to tag this record!